<DOC>
	<DOCNO>NCT01384058</DOCNO>
	<brief_summary>It interest ezetimibe alone combination statin may influence atherogenic dense Low Density Lipoprotein ( dLDL ) patient type 2 diabetes mellitus . The primary objective study whether change concentration Apolipoprotein B ( ApoB ) dLDL baseline 3 treatment group .</brief_summary>
	<brief_title>Effect Ezetimibe Simvastatin Both Low Densitiy Lipoprotein -Subfractions Patients With Type 2 Diabetes</brief_title>
	<detailed_description>The selective cholesterol resorption inhibitor ezetimibe belong new class cholesterol lower drug . It interest ezetimibe alone combination statin may influence atherogenic dense Low Density Lipoprotein ( dLDL ) patient type 2 diabetes mellitus . The primary objective study whether change concentration Apolipoprotein B ( ApoB ) dLDL baseline 3 treatment group . The comparison treatment group exploratory due insufficient power detect change treatment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>men &gt; 18 ≤ 75 year postmenopausal woman ≤ 75 year ( follicle stimulate hormone ( FSH ) &gt; 30 mIU/ml , woman &gt; 60 year FSH &gt; 20 mIU/ml ) well control diabetes mellitus type II ( glycohaemoglobin ≤ 8,0 % ) LDLcholesterol ≤ 160 mg/dl LDLsubfractions : concentration apoB100 dLDL ( LDL5 und LDL6 ) &gt; 25 mg/dl write informed consent participation clinical trial within last 30 screen visit patient unable give write informed consent Body mass index &lt; 15 kg/m² &gt; 35 kg/m² clinical atherosclerotic disease ( coronary heart disease , peripheral artery disease , carotid artery disease ) malignoma uncontrolled arterial hypertension ( &gt; 160/ &gt; 100 mmHg ) clinically relevant disease liver and/or kidney clinically relevant endocrinally hematologic problem allergy study medication ( Ezetimibe and/or Simvastatin ) alcohol drug abuse laboratory : alanine aminotransferase , aspartate aminotransferase , total bilirubin &gt; 3 x ULN , creatine kinase &gt; 5 x ULN Concurrent treatment potent CYP3A4inhibitors ( e.g . itraconazole , ketoconazole , HIVproteaseinhibitors , erythromycin , clarithromycin , telithromycin und nefazodone ) relevant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>atherogenic lipoprotein</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>small , dense LDL</keyword>
</DOC>